Jacqueline C. Jones, Jeff S. Coombes, Graeme A. Macdonald – 5 December 2011 – Exercise capacity and muscle strength are predictors of outcome in a number of clinical populations. Advanced liver disease is a catabolic state, and patients often have muscle wasting. However, the relationships between exercise capacity, strength, and outcomes for patients undergoing liver transplantation are poorly understood.
C. Burcin Taner, Darrin L. Willingham, Ilynn G. Bulatao, Timothy S. Shine, Prith Peiris, Klaus D. Torp, Juan Canabal, Justin H. Nguyen, David J. Kramer – 5 December 2011 – The continuation of hemodynamic, respiratory, and metabolic support for a variable period after liver transplantation (LT) in the intensive care unit (ICU) is considered routine by many transplant programs. However, some LT recipients may be liberated from mechanical ventilation shortly after the discontinuation of anesthesia.
Monica Franciosi, Lucio Caccamo, Paolo De Simone, Antonio Daniele Pinna, Giovanni Giuseppe Di Costanzo, Riccardo Volpes, Vincenzo Scuderi, Paolo Strignano, Patrizia Boccagni, Patrizia Burra, Antonio Nicolucci, for the TWINS I Study Group – 5 December 2011 – To date, there is still a lack of instruments for specifically assessing the impact of anti–hepatitis B virus prophylaxis after liver transplantation (LT) on health‐related quality of life (HRQOL) and treatment satisfaction.
Nicole T. do O, Dennis Eurich, Petra Schmitz, Maximilian Schmeding, Christoph Heidenhain, Marcus Bahra, Christian Trautwein, Peter Neuhaus, Ulf P. Neumann, Hermann E. Wasmuth – 5 December 2011 – Fibrosis recurrence after liver transplantation (LT) for hepatitis C virus (HCV) is a universal event and strongly determines a patient's prognosis. The recipient risk factors for fibrosis recurrence are still poorly defined. Here we assess a genetic risk score as a predictor of fibrosis after LT.
Corlan O. Adebajo, Jayant A. Talwalkar, John J. Poterucha, W. Ray Kim, Michael R. Charlton – 5 December 2011 – Ultrasound‐based transient elastography (TE) is a promising noninvasive alternative to liver biopsy for the detection of hepatic fibrosis due to recurrent hepatitis C virus (HCV) after liver transplantation (LT). However, its overall test performance in various settings remains unknown.
Richard Ruiz, Koji Tomiyama, Jeffrey Campsen, Robert M. Goldstein, Marlon F. Levy, Greg J. McKenna, Nicholas Onaca, Brian Susskind, Glenn W. Tillery, Goran B. Klintmalm – 5 December 2011 – Whether a positive crossmatch result has any relevance to liver transplantation (LT) outcomes remains controversial. We assessed the impact of a positive crossmatch result on patient and graft survival and posttransplant complications. During a 20‐year period, 2723 LT procedures with crossmatch results were identified: 2479 primary transplants and 244 retransplants.
Vanessa Sauer, Ramsi Siaj, Sandra Stöppeler, Ralf Bahde, Hans‐Ullrich Spiegel, Gabriele Köhler, Andree Zibert, Hartmut H.‐J. Schmidt – 5 December 2011 – The outcome of consecutive hepatocyte transplants was explored in a rat model of Wilson's disease before the onset of fulminant hepatitis without preconditioning regimens. Rats received a high‐copper diet in order to induce a rapid induction of liver failure. Sham‐operated rats (15/15) developed jaundice and fulminant hepatitis, and they died within 4 weeks of first transplantation.
Umberto Baccarani, Stefania Bidinost, Marcello Tavio, Pierluigi Viale, Gian Luigi Adani – 5 December 2011
Benjamin L. Shneider – 5 December 2011 – Sclerosing cholangitis, an uncommon disorder in children, is progressive and is, therefore, an important indication for pediatric liver transplantation. This review summarizes current challenges in the diagnosis and treatment of this rare form of pediatric liver disease. Liver Transpl 18:277–281, 2012. © 2011 AASLD.
Lakhbir Sandhu, Charbel Sandroussi, Markus Guba, Markus Selzner, Anand Ghanekar, Mark S. Cattral, Ian D. McGilvray, Gary Levy, Paul D. Greig, Eberhard L. Renner, David R. Grant – 5 December 2011 – Several studies have reported higher rates of recurrent hepatocellular carcinoma (HCC) after living donor liver transplantation (LDLT) versus deceased donor liver transplantation (DDLT). It is unclear whether this difference is due to a specific biological effect unique to the LDLT procedure or to other factors such as patient selection.